JP7466544B2 - テトラサイクリン化合物を使用してマイコバクテリア感染症を処置する方法 - Google Patents

テトラサイクリン化合物を使用してマイコバクテリア感染症を処置する方法 Download PDF

Info

Publication number
JP7466544B2
JP7466544B2 JP2021536672A JP2021536672A JP7466544B2 JP 7466544 B2 JP7466544 B2 JP 7466544B2 JP 2021536672 A JP2021536672 A JP 2021536672A JP 2021536672 A JP2021536672 A JP 2021536672A JP 7466544 B2 JP7466544 B2 JP 7466544B2
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
mycobacterial
omadacycline
tetracycline compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021536672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021536504A (ja
JPWO2020051151A5 (https=
JP2021536504A5 (https=
Inventor
シナモン，マイケル，ヘンリー
ドレイパー，マイケル，ピー．
スティーンバーゲン，ジュディス，エヌ．
タナカ，エス．，ケン
Original Assignee
パラテック ファーマシューティカルズ，インコーポレイテッド
ユナイテッド ステイツ ガバメント アズ レプリゼンテッド バイ ザ デパートメント オブ ベテランズ アフェアーズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パラテック ファーマシューティカルズ，インコーポレイテッド, ユナイテッド ステイツ ガバメント アズ レプリゼンテッド バイ ザ デパートメント オブ ベテランズ アフェアーズ filed Critical パラテック ファーマシューティカルズ，インコーポレイテッド
Publication of JP2021536504A publication Critical patent/JP2021536504A/ja
Publication of JPWO2020051151A5 publication Critical patent/JPWO2020051151A5/ja
Publication of JP2021536504A5 publication Critical patent/JP2021536504A5/ja
Priority to JP2024059527A priority Critical patent/JP2024084794A/ja
Application granted granted Critical
Publication of JP7466544B2 publication Critical patent/JP7466544B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2021536672A 2018-09-04 2019-09-03 テトラサイクリン化合物を使用してマイコバクテリア感染症を処置する方法 Active JP7466544B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024059527A JP2024084794A (ja) 2018-09-04 2024-04-02 テトラサイクリン化合物を使用してマイコバクテリア感染症を処置する方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862726738P 2018-09-04 2018-09-04
US62/726,738 2018-09-04
US201862731410P 2018-09-14 2018-09-14
US62/731,410 2018-09-14
US201862746039P 2018-10-16 2018-10-16
US62/746,039 2018-10-16
US201862760131P 2018-11-13 2018-11-13
US62/760,131 2018-11-13
PCT/US2019/049368 WO2020051151A1 (en) 2018-09-04 2019-09-03 Methods of treating mycobacterial infections using tetracycline compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024059527A Division JP2024084794A (ja) 2018-09-04 2024-04-02 テトラサイクリン化合物を使用してマイコバクテリア感染症を処置する方法

Publications (4)

Publication Number Publication Date
JP2021536504A JP2021536504A (ja) 2021-12-27
JPWO2020051151A5 JPWO2020051151A5 (https=) 2022-09-06
JP2021536504A5 JP2021536504A5 (https=) 2022-09-06
JP7466544B2 true JP7466544B2 (ja) 2024-04-12

Family

ID=69722600

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021536672A Active JP7466544B2 (ja) 2018-09-04 2019-09-03 テトラサイクリン化合物を使用してマイコバクテリア感染症を処置する方法
JP2024059527A Pending JP2024084794A (ja) 2018-09-04 2024-04-02 テトラサイクリン化合物を使用してマイコバクテリア感染症を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024059527A Pending JP2024084794A (ja) 2018-09-04 2024-04-02 テトラサイクリン化合物を使用してマイコバクテリア感染症を処置する方法

Country Status (13)

Country Link
US (2) US12161655B2 (https=)
EP (1) EP3846805A4 (https=)
JP (2) JP7466544B2 (https=)
KR (2) KR20260036400A (https=)
CN (1) CN113164456A (https=)
AU (2) AU2019335203B2 (https=)
BR (1) BR112021004057A2 (https=)
CA (1) CA3111447A1 (https=)
MA (1) MA53564A (https=)
MX (2) MX2021002503A (https=)
PH (1) PH12021550452A1 (https=)
SG (1) SG11202102149SA (https=)
WO (1) WO2020051151A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7840880B2 (ja) * 2020-06-11 2026-04-06 パラテック ファーマシューティカルズ，インコーポレイテッド オマダサイクリンの結晶形態、その合成方法及びその使用方法
TW202237116A (zh) * 2020-12-02 2022-10-01 日商塩野義製藥股份有限公司 以組合細胞色素bc1抑制劑與克拉黴素或阿奇黴素為特徵之用於治療分枝桿菌感染之藥物
JP2024511419A (ja) * 2021-03-24 2024-03-13 インスメッド インコーポレイテッド 非結核性抗酸菌肺疾患を治療するための併用療法
WO2025221846A1 (en) * 2024-04-18 2025-10-23 St. Jude Children's Research Hospital, Inc. Compositions and methods for treating non-tuberculosis mycobacteria infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018051102A1 (en) 2016-09-15 2018-03-22 Antibiotx A/S Combinations comprising dibromopropamidine or diminazene and a tetracycline anti-bacterial agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009175B1 (ru) 2000-07-07 2007-12-28 Трастис Оф Тафтс Коллидж Замещенные соединения миноциклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния млекопитающего
US7553828B2 (en) 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
US20060194773A1 (en) 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
EP2311451A1 (en) 2002-03-08 2011-04-20 Paratek Pharmaceuticals, Inc. Amino-methyl substituted tetracycline compounds
PT2271348T (pt) * 2008-03-28 2018-04-16 Paratek Pharm Innc Formulação de comprimido oral de composto de tetraciclina
TWI680117B (zh) 2008-05-19 2019-12-21 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
KR101732084B1 (ko) 2011-07-26 2017-05-02 케이비피 바이오사이언시즈 씨오., 엘티디. 9-아미노메틸 치환된 테트라사이클린 화합물
JP2015527403A (ja) 2012-09-11 2015-09-17 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｉｖプロテアーゼ阻害剤
CA3018872A1 (en) * 2016-03-24 2017-09-28 Paratek Pharmaceuticals, Inc. Methods of treating a bacterial infection in a subject at risk of developing c. difficile infection
JP2019514952A (ja) * 2016-05-02 2019-06-06 パラテック ファーマシューティカルズ，インコーポレイテッド ９−アミノメチルミノサイクリン化合物及び尿路感染症（ｕｔｉ）の処置におけるその使用方法
TW202206081A (zh) * 2016-08-03 2022-02-16 美商派瑞泰Ｓｐｖ２有限公司 ９—胺甲基米諾四環素化合物及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018051102A1 (en) 2016-09-15 2018-03-22 Antibiotx A/S Combinations comprising dibromopropamidine or diminazene and a tetracycline anti-bacterial agent

Also Published As

Publication number Publication date
JP2021536504A (ja) 2021-12-27
US20210346408A1 (en) 2021-11-11
EP3846805A1 (en) 2021-07-14
CN113164456A (zh) 2021-07-23
US20250332178A1 (en) 2025-10-30
US12161655B2 (en) 2024-12-10
MX2021002503A (es) 2021-06-15
AU2025234215A1 (en) 2025-10-16
KR20260036400A (ko) 2026-03-16
AU2019335203B2 (en) 2025-06-19
KR102933150B1 (ko) 2026-03-03
BR112021004057A2 (pt) 2021-05-25
EP3846805A4 (en) 2022-08-24
MA53564A (fr) 2021-07-14
WO2020051151A1 (en) 2020-03-12
SG11202102149SA (en) 2021-04-29
PH12021550452A1 (en) 2021-12-06
MX2024008671A (es) 2024-07-23
JP2024084794A (ja) 2024-06-25
CA3111447A1 (en) 2020-03-12
KR20210090160A (ko) 2021-07-19
AU2019335203A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
JP2024084794A (ja) テトラサイクリン化合物を使用してマイコバクテリア感染症を処置する方法
CA2842777A1 (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
JP5470245B2 (ja) バイオフィルム形成の処置のためのトリアゾール化合物
KR20260022303A (ko) 항박테리아제들을 포함하는 약학적 조합 및 이의 조성물
JP2002500189A (ja) 微生物の院内感染症の治療用医薬の製造におけるタウロリジンまたはタウラルタムのような抗微生物薬剤の使用
JP2020533417A (ja) 抗菌組成物
KR101850265B1 (ko) 항균제 및 타조박탐을 포함하는 조성물
JP5276653B2 (ja) カルバペネム類を含む殺菌性抗ｍｒｓａ活性医薬組成物
RU2831120C2 (ru) Способы лечения микобактериальных инфекций с применением тетрациклиновых соединений
CN105792827B (zh) 抗菌组合物
JP2016538262A (ja) 抗菌剤を含む医薬品組成物
JP2017506240A (ja) 抗菌剤を含む医薬組成物
JP2017507162A (ja) 抗菌薬を含む医薬組成物
JP2016535038A (ja) 抗菌剤を含む医薬品組成物
JP2017508769A (ja) セフェピムまたはスルバクタムを含む医薬組成物
HK1146223A (en) Triazol compounds for treating biofilm formation

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20210609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230725

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240402

R150 Certificate of patent or registration of utility model

Ref document number: 7466544

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150